FCCC LOGO Faculty Publications
Emmanouilides C , Witzig TE , Wiseman GA , Gordon LI , Wang H , Schilder R , Saville MW , Flinn I , Molina A
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-hodgkin's lymphoma
Cancer Biotherapy and Radiopharmaceuticals. 2007 Oct;22(5) :684-691
Back to previous list
Abstract
Objective: Treatment-related complications are more common in older patients with non-Hodgkin's lymphoma (NHL), often leading to chemotherapy modifications that can compromise efficacy. We analyzed data from clinical trials of yttrium-90-ibritumomab tiuxetan (Zevalin((R)) Biogen Idec, Cambridge, MA) to determine its safety and efficacy in older patients with NHL. Design and Methods: Data on safety and efficacy from four clinical trials of Y-90-ibritumomab tiuxetan in 211 patients with NHL were pooled and analyzed by ages of <60, 60-69, and >= 70 years. Results: Patients >= 70 years had a similar incidence of grade 3 or 4 neutropenia (68% vs. 66%), thrombocytopenia (68% vs. 70%), anemia (8% vs. 22%), and nonhematologic adverse events (23% vs. 19%) as that observed in patients <60 years. Response rates (range, 71%-80%) and the durations of response (median of 9.9, 11.0, and 9.4 months) were similar in the three groups. Conclusions: Yttrium-90-ibritumomab tiuxetan produces h!
Notes
Emmanouilides, Christos Witzig, Thomas E. Wiseman, Gregory A. Gordon, Leo I. Wang, Hua Schilder, Russell Saville, M. Wayne Flinn, Ian Molina, Arturo MARY ANN LIEBERT INC